结合 石药集团 披露的业绩报告来看，其近年业绩呈现阶段性承压态势。据公司公告及财报数据显示，2025年上半年其实现营业收入136.93亿元、归母净利润25.48亿元；而2024年全年营收为290.09亿元，同比下滑7.8%，归母净利润43.28亿元，同比减少 26.3%，这是其近10年来首次出现营收净利双双下滑的情况。作为营收占比77%的核心板块，成药业务上半年表现承压。据公司中期财报显示，该板块...
Source Link结合 石药集团 披露的业绩报告来看，其近年业绩呈现阶段性承压态势。据公司公告及财报数据显示，2025年上半年其实现营业收入136.93亿元、归母净利润25.48亿元；而2024年全年营收为290.09亿元，同比下滑7.8%，归母净利润43.28亿元，同比减少 26.3%，这是其近10年来首次出现营收净利双双下滑的情况。作为营收占比77%的核心板块，成药业务上半年表现承压。据公司中期财报显示，该板块...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.